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a b s t r a c t
Objectives: Apathy is common, impactful, and difficult to manage in people with dementia. We evaluated
the efficacy of nonpharmacological interventions, exercise, and social interaction, in combination with
antipsychotic review, to reduce apathy in people with dementia living in nursing homes in a cluster
randomized controlled trial (RCT).
Methods: Well-being and health for people with dementia (WHELD) program included a 2  2  2
factorial cluster RCT involving people with dementia living in 16 nursing homes in the United Kingdom.
All homes received training in person-centered care, and were randomized to receive antipsychotic
review, social interaction, and exercise, either alone or in combinations. Apathy was one of the secondary
outcomes of the WHELD trial, and it was measured by the Neuropsychiatric Inventoryenursing home
version at baseline and 9 months (n ¼ 273). We used multilevel mixed effects linear regression models to
assess the impact of the interventions on apathy.
Results: Prevalence of apathy was 44.0% (n ¼ 120; 95% confidence interval [CI] 38.1%e49.9%) at baseline.
Severity of apathy had significant positive correlations with dementia severity, neuropsychiatric symp-
toms, depressive symptoms, agitation, and the needs of the people with dementia (P < .001). Antipsy-
chotic review reduced antipsychotic use, but it significantly increased apathy (b ¼ 5.37; SE ¼ 0.91;
P < .001). However, antipsychotic review in combination with either social interaction (b ¼ 5.84;
SE ¼ 1.15; P < .001) or exercise (b ¼ 7.54; SE ¼ 0.93; P < .001) significantly reduced apathy.
Conclusions: Antipsychotic review can play a significant role in improving apathy in people with de-
mentia living in nursing homes, when combined with psychosocial interventions such as social inter-
action and exercise. Guidance must be adapted to reflect this subtlety in care.
 2016 AMDA e The Society for Post-Acute and Long-Term Care Medicine.
Dementia affects 35 million people around the world. As the con-
dition progresses, many individuals move to reside in long-term care
facilities. In the United Kingdom, these people account for one-third of
people with dementia,1 whereas 64% of people receiving Medicare in
US nursing homes have dementia.2 These individuals have complex
needs due to the unique set of cognitive and functional impairments
that characterize moderate to severe dementia. These are further
compounded by neuropsychiatric symptoms, medical comorbidity,
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and loss of communication ability.3 Neuropsychiatric symptoms affect
90% of people with dementia at some point, and are particularly im-
pactful with individuals requiring additional support to intiate and
engage with activities.4 Apathy is possibly the most frequent neuro-
psychiatric symptom, but is relatively underresearched.
Apathy is not merely a symptom, but a multidimensional syn-
drome affecting cognitive, emotional, and behavioral domains,5,6 and
it causes clinically significant functional impairment in many people
with dementia.7 It is widely prevalent, persistent, and therapeutically
challenging in people with dementia,8 especially those with moderate
to severe dementia living in nursing homes.9 A recent systematic re-
view including 28 studies reported the mean prevalence of apathy in
people with dementia living in nursing homes to be 36% (range: 17%e
82%).9 Moreover, apathy is associated with high levels of disability,
faster cognitive and functional decline, weight loss, poor quality of life,
high caregiver burden, poor quality of care, poor rehabilitation, and
increased risk of mortality.8,10e13
Systematic research on the management of apathy remains
sparse.10,14 Acetylcholinesterase inhibitors have level II evidence to
support their efficacy.14 In the context of an increasing effort to reduce
the use of antipsychotic medications in people with dementia, avail-
able evidence does not support the use of antipsychotics to treat
apathy.14e16 The literature regarding nonpharmacological treatments
for apathy is limited,10 but some preliminary studies indicate the
potential of tailored therapeutic mentally stimulating activities,17 ex-
ercise,18 and social interaction.19
As a part of a cluster randomized controlled trial (RCT) focusing on
people with dementia in nursing homes, we examined the impact of a
pragmatic intervention to review antipsychotic medication. The initial
results confirmed that this intervention could achieve a significant
reduction in antipsychotic use, and that in combination with social
interaction there was also a significant reduction in mortality. There
was, however, a significant worsening in agitation and overall psy-
chiatric symptoms, which was mitigated by social interaction and/or
exercise.20 This article examined the frequency of apathy, determined
whether review of antipsychotic medication led to any worsening of
apathy, and whether this could be mitigated by evidence-based
nonpharmacological interventions.
Material and Methods
Study Design
The Well-being and Health for people with Dementia (WHELD)
program included this cluster RCT with 2  2  2 factorial designwith
2 replications.21 As the methodology used in this study has been re-
ported in detail elsewhere,20 it is only briefly presented here. The unit
of randomization was the nursing home. Each nursing home (cluster)
received a randomly allocated intervention, with most homes
randomly assigned tomore than 1 of the 3 interventions, for 9months.
The study received ethical approval from South-Central Oxford
Research Ethics Committee C (REC number 11/SC0066). The trial is
registered as a clinical trial (ISRCTN number 40313497), and the
protocol is available online at http://www.kcl.ac.uk/ioppn/depts/
wolfson/about/people/staff/ballardclive.aspx.
Setting
This study was conducted in 16 nursing homes in the United
Kingdom. Each care home represented a cluster that received a
randomly allocated intervention for 9 months. These nursing homes
were identified from those rated “adequate” or better in the care
quality commission register in 2013, in the Oxfordshire, Buck-
inghamshire, and London localities. Eight homes were selected by
probability sampling, and the remaining 8 were selected by
nonprobability sampling. We excluded the nursing homes if fewer
than 60% of their residents had dementia or they were in receipt of
local authority special support.
Participants
All residents meeting eligibility criteria were invited to participate.
Eligibility criteria included the diagnosis of dementia, defined by the
Clinical Dementia Rating Scale (CDRS)22 stage 1 or greater, and by
Functional Assessment Staging (FAST)23 stage 4 or greater. Consent for
nursing home involvement was obtained from themanagement of the
homes. If residents lacked capacity to consent, informed consent was
obtained with the involvement of a nominated or personal consultee
who represented the residents’ interests and wishes in accordance
with the Mental Capacity Act. Study interventions were delivered to
all residents, with a minimum recruitment target of 12 participants
per nursing home. The impact of study interventions on antipsychotic
use, agitation, depression, neuropsychiatric symptoms, and mortality
of these participants have already been reported elsewhere.20
Interventions
WHELD therapists worked with care staff nominated as dementia
champions in each home to implement the following 4 interventions:
(1) Person-Centred Care (PCC): PCC was implemented using the tools
from the Focused Intervention for Training of Staff manual,24 based on
evidence-based approaches for improving care in nursing homes, and
from a review of other best available training manuals with the aim of
personalizing and tailoring care practice in line with individual pref-
erences and needs.25 (2) Antipsychotic review: The WHELD therapists
helped the homes’ dementia champions to develop effective processes
within the nursing homes to prompt antipsychotic review according
to the best practice guidelines. Moreover, they worked with the
physicians and nursing home staff to augment PCC during the anti-
psychotic withdrawal period. The participants’ primary care physicans
or specialist psychiatrists reviewed long-term prescriptions of anti-
psychotics on the basis of the National Institute for Health and Care
Excellence (NICE) dementia guidelines26 and of the antipsychotic care
pathway, developed by the Alzheimer’s Society in partnership with
the Department of Health.27 These guidelines emphasized careful
medical assessment of underlying causes of neuropsychiatric symp-
toms, such as pain and factors leading to delirium, the use of non-
pharmacological interventions as a first-line approach before
considering pharmacotherapy (unless symptoms were severe or
involving immediate risks), regular review of antipsychotic pre-
scriptions in people on long-term antipsychotic medications, and the
recommendation to constrain treatment periods with newly
commenced antipsychotics to a maximum duration of 12 weeks. A
trial discontinuation was recommended as the preferred practice for
patients who had had antipsychotic prescriptions for more than
3 months, but caution was recommended in people with baseline
Neuropsychiatric Inventory scores above 14 on the basis of evidence
from a previous RCT.28 (3) Exercise: Enjoyable positive physical activ-
ities were encouraged on the basis of the Seattle protocols,29 and
exercise elements of the Needs Environment Stimulation Techniques
(NEST) manual.30 Previous and current interests of the participants,
and their current level of health and fitness were assessed. The aim
was for participants to be engaged in at least 1 hour of exercise per
week. If they were doing this at baseline, the amount of exercise was
increased by 20% by the end of the intervention period. (4) Social
interaction with pleasant activities: A social interaction intervention
manual was developed on the basis of three evidence-based ap-
proaches, the positive events schedule from the Seattle protocols,29
the social activities elements of the NEST manual,30 and the social
interaction intervention, developed by Cohen-Mansfield and
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colleagues.31 Individualized plans for activities and staff-resident in-
teractions were developed using a life history appproach and assess-
ment of current interests. The aim was for participants to be engaged
in at least 1 hour of social interaction per week. If this was taking place
at baseline, the amount of social interaction was increased by 20% by
the end of the intervention period.
Randomization
All 16 nursing homes received PCC. After constrained complete list
randomization, stratified on the 3 participating sites,32 antipsychotic
review, exercise, and social interaction were implemented in 8 care
homes each. The constraint ensured an approximately equal distri-
bution of the number of study interventions to each geographic
location. Eight nursing homes were randomly assigned to antipsy-
chotic review, 8 to an intervention to increase social interaction, and 8
to an exercise intervention. Each possible combination of in-
terventions was assigned to 2 nursing homes exclusively. A trained
WHELD therapist coordinated each intervention into the 8 nursing
homes that were randomized to receive that intervention. In each
nursing home, a minimum of 2 lead care staff members were trained
to implement that intervention.
Outcome Measures
Apathywas one of the outcomes of theWHELD trial, and it waswas
assessed by the Neuropsychiatric InventoryeNursing Home version
(NPI-NH).33 G domain of the NPI-NH evaluated apathy over the
4 weeks before assessment using a screening question, and 7 sub-
questions. When apathy was identified, NPI-NH documented its fre-
quency on a 4-point scale, and its severity on a 3-point scale. An
apathy domain score was calculated by multiplying frequency and
severity scores. This score was zero when apathy was absent, and it
ranged from 1 to 12, when apathy was present. Depression, anxiety,
and agitation of the participants were evaluated using the Cornell
Scale for Depression in Dementia (CSDD),34 Rating Anxiety In De-
mentia (RAID),35 and Cohen-Mansfield Agitation Inventory (CMAI),36
respectively. Needs and quality of life of the participants were sys-
tematically assessed using the Camberwell Assessment of Need for the
Elderly (CANE)37 and assessment of quality of life for people with
dementia (DEMQoL),38 respectively. Assessments were carried out at
baseline before randomization, and after the completion of 9 month-
long interventions by research assistants, blind to intervention allo-
cation. The factorial designwith all nursing homes receiving at least 1
intervention helped in maintaining the blinding.
Statistical Analyses
We analyzed the data from the WHELD cluster RCT using data
pertaining to apathy from the same randomized participants reported
previously.20 Participants’ characteristics, their clinical profile, and
apathy scores were initially analyzed by descriptive statistics. Missing
values of items within the study questionnaires were replaced with
the mean scores of the remaining items in the questionnaires as long
Included Lost
852
255 were ineligible (no dementia)
597Total meeting eligibility 
criteria
304 did not give consent
293Number with consent 
given for trial
13 (two homes, with 9 and 4 
participants, respectively) withdrew 
and were replaced, 1 died, 2 were 
found not having dementia, 4 could 
not be assessed for apathy at 
baseline
273Number at baseline
60 died, 13 moved out of home, and 
9 withdrew
191Number followed up
Total in homes
Fig. 1. CONSORT diagram showing flow of participants.
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as the number of missing items did not exceed 20% of the total number
of items in the questionnaires. Prevalence of apathy at baseline was
compared with that after the 9-month intervention period using the
McNemar test. Statistical significance of difference between the NPI-
NH G domain apathy scores at the 2 time points was analyzed by
the Wilcoxon signed-rank test. Appropriate statistical tests of signifi-
cance were used to analyze the observed differences between the
participants with and without apathy. Correlations between apathy
scores and CDR, FAST, CSDD, RAID, CMAI, CANE, and DEMQoL scores
were assessed using the Spearman rank-order correlation with Bon-
ferroni corrections at baseline and after the 9-month intervention
period.
The impact of antipsychotic review on apathy in people with
dementia living in nursing homes was analyzed by multilevel mixed
effects linear regression models with maximum likelihood estima-
tion method. Further analyses were undertaken to determine the
impact of combining antipsychotic review with social interaction or
exercise. Individual participants were nested within a higher level,
the nursing homes. Differences between the NPI-NH apathy scores at
the 2 time points was the outcome variable. Study interventions
were the independent variables. Age and gender of the participants,
as well as FAST and CSDD scores at baseline were included as cova-
riates. Although FAST stages were naturally ordered, they were
modeled as linear effects to increase the power of the statistical
analyses. Participants who did not receive any interventions except
the PCC intervention formed the reference group. Clustered robust
standard errors for the estimated regression coefficients were
calculated with the nursing homes as the clustering variable. Only
the participants who completed the 9-month intervention period
were included in these analyses. We repeated these analyses by
including only the participants with moderately severe and severe
dementia, defined by FAST stages 6 and 7 at baseline. All analyses
were performed using the statistical software STATA 13.1 (StataCorp,
College Station, TX).
Results
Participant Characteristics
A total of 273 people with dementia living in 16 nursing homes
were assessed for apathy at baseline, and 191 (70.0%) of them
completed the 9-month intervention period. Figure 1 presents the
participant flow diagram of the WHELD RCT. Presence of apathy at
baseline was not significantly associated with death (c2¼ 0.10; df¼ 1;
P ¼ .75), but was significantly associated with withdrawal from the
study (c2 ¼ 8.04; df ¼ 1; P ¼ .005). Table 1 presents the baseline
characteristics of participants with and without apathy; 73.6% (95%
confidence interval [CI] 68.0%e78.5%) of the participants were
women, and 89.0% (95% CI 84.7%e92.2%) of them were Caucasian.
Mean age of the participants was 85.3 (95% CI 84.4e86.1) years at
baseline. Age of the participants did not differ significantly among the
16 nursing homes (Kruskal-Wallis c2 ¼ 16.18; df ¼ 15; P ¼ .37). Table 2
presents baseline characteristics of the participants who received and
did not receive antipsychotic review, social interaction, and exercise.
Prevalence and Correlates of Apathy
A total of 120 participants (44.0%; 95% CI 38.1%e49.9%) had
apathy at baseline. Mean NPI-NH G domain apathy scores at baseline
was 2.32 (95% CI 1.91e2.73). Participants with and without apathy at
baseline did not differ significantly in gender, age, ethnicity, number
of years living in the nursing homes, or the current prescription of
antipsychotic medications. Table 3 presents the correlations between
NPI-NH apathy scores and severity of dementia, neuropsychiatric
symptoms, depressive symptoms, anxiety symptoms, agitation,
quality of life, and the needs of the people with dementia at baseline
and after the 9-month intervention period. Severity of apathy at
baseline showed significant positive correlations with severity of
dementia, overall neuropsychiatric symptoms, depression, agitation,
and overall needs after Bonferroni corrections (P< .001). A total of 85
participants (44.5%; 95% CI 37.5%e51.7%) had apathy after the 9-
month intervention period. Mean NPI-NH apathy score at follow-
up was 2.60 (95% CI 2.08e3.13). Categorical presence of apathy
among the participants did not change significantly between the 2
time points (McNemar c2 ¼ 0.47; df ¼ 1; P ¼ .49), and the numerical
increase in the NPI-NH apathy scores at follow-up was not statisti-
cally significant (Wilcoxon matched-pairs signed-rank test z ¼ 1.48;
P ¼ .14). However, increased apathy correlated with increased
severity of dementia (rs ¼ 0.15; P ¼ .04), and with increased needs of
the people with dementia (rs ¼ 0.20; P ¼ .007) between the 2 time
points. Moreover, it showed significant negative correlation with the
changes in the quality of life for the people with dementia during the
study (rs ¼ 0.15; P ¼ .04).
Impact of Antipsychotic Review on Apathy
Antipsychotic review alone significantly increased apathy
(b ¼ 5.37; SE ¼ 0.91; P < .001), (Cohen’s d ¼ 0.97). However, anti-
psychotic review in combination with either social interaction
(Cohen’s d ¼ 0.49) or exercise (Cohen’s d ¼ 0.20) reduced apathy, and
this reduction was statistically significant, after adjusting for the ef-
fects of age, gender, baseline dementia severity, and baseline
depressive symptoms (Table 4). Further analyses including only the
participants with moderately severe and severe dementia confirmed
that antipsychotic review (b ¼ 6.75; SE ¼ 1.31; P < .001), when
delivered alone, significantly increased the severity of apathy, and that
antipsychotic review in combination with either social interaction
(b ¼ 6.59; SE ¼ 1.58; P < .001) or exercise (b ¼ 10.51; SE ¼ 1.32;
P < .001) significantly reduced the severity of apathy, after adjusting
for the effects of age, gender, baseline dementia severity, and baseline
depressive symptoms. Moreover, analyses including only the
Table 1
Baseline Characteristics of Participants With (n ¼ 120) and Without Apathy
(n ¼ 153)
Characteristic Without Apathy,
n (%)/Mean (SD)
With Apathy,*
n (%)/Mean (SD)
c2/ty/zz P
Female gender 113 (73.9) 88 (73.3) 0.01 .92
Age, y 85.7 (6.8) 84.7 (7.0) 1.13z .26
Ethnicity: White 136 (88.9) 107 (89.2) 0.01 .94
Years lived in
nursing homes
2.1 (2.0) 2.5 (2.2) 1.21z .22
CDR 25.34 <.001
Mild, 0.5e1 28 (18.3) 5 (4.2)
Moderate, 2 72 (47.1) 40 (33.3)
Severe, 3 53 (34.6) 75 (62.5)
FAST 15.35 .002
Mild 25 (16.3) 5 (4.2)
Moderate 12 (7.8) 4 (3.3)
Moderately severe 94 (61.4) 82 (68.3)
Severe 22 (14.4) 29 (24.2)
NPI-NH total scorex 9.7 (11.4) 25.5 (18.5) 8.72z <.001
CMAI total score 43.7 (15.0) 53.8 (17.5) 5.07z <.001
CSDD total score 4.2 (4.2) 6.1 (4.6) 4.03z <.001
RAID total score 4.5 (4.4) 6.0 (5.6) 2.24z .03
CANE total number
of needs
14.4 (2.4) 16.1 (2.8) 5.38y <.001
DEMQoL total score 105.4 (12.2) 102.6 (12.6) 2.13z .03
Currently on
antipsychotics
22 (14.4) 26 (21.7) 2.46 .12
*NPI-NH G domain, apathy, score above 0.
yTwo-sample t test with equal variances.
zTwo-sample Wilcoxon rank-sum test z value; CDR, FAST.
xTotal score of all 12 domains of the NPI-NH.
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participants who did not receive any antipsychotics at the baseline
confirmed that antipsychotic review (b ¼ 4.24; SE ¼ 1.55; P ¼ .006),
when delivered alone, significantly increased the severity of apathy,
and that antipsychotic review in combination with either social
interaction (b ¼ 4.10; SE ¼ 1.86; P ¼ .03) or exercise (b ¼ 8.93;
SE ¼ 1.97; P < .001) significantly reduced the severity of apathy, after
adjusting for the effects of age, gender, baseline dementia severity,
and baseline depressive symptoms.
Apathy and Depression
Mean CSDD score of the people with dementia was 5.00 (95% CI
4.46e5.54) at baseline, and 4.59 (95% CI 3.93e5.25) after the 9-month
intervention period (Wilcoxon matched-pairs signed-rank test
z ¼ 0.07; P ¼ .94). Correlation between the changes in the severity of
apathy and the changes in the severity of depressive symptoms during
the study was not statistically significant (rs ¼ 0.08; P ¼ .30). Changes
in the severity of apathy between the 2 time points did not signifi-
cantly change the severity of depressive symptoms (b ¼ 0.10;
SE ¼ 0.08; P ¼ .22), after adjusting for the effects of age, gender, and
baseline dementia severity of the participants.
Discussion
This study has confirmed that apathy is common in people with
dementia living in nursing homes, and identified significant corre-
lations with the severity of dementia and other neuropsychiatric
Table 2
Baseline Characteristics of Participants Who Received and Did Not Receive Antipsychotic Review, Social Interventions, and Exercise
Characteristic AR (n ¼ 143)
n (%)/Mean (SD)
No AR (n ¼ 130)
n (%)/Mean (SD)
SI (n ¼ 138)
n (%)/Mean (SD)
No SI (n ¼ 135)
n (%)/Mean (SD)
EX (n ¼ 136)
n (%)/Mean (SD)
No EX (n ¼ 137)
n (%)/Mean (SD)
Female gender 107 (74.8) 94 (72.3) 94 (68.1) 107 (79.3) 92 (67.7) 109 (80.0)
Age, y 85.4 (6.9) 85.1 (7.0) 84.7 (7.3) 85.8 (6.4) 85.3 (6.5) 85.2 (7.3)
Ethnicity: White 129 (90.2) 114 (87.7) 118 (85.5) 125 (92.6) 118 (86.8) 125 (91.2)
Years lived in nursing homes 2.5 (2.1) 2.1 (2.1) 2.4 (2.4) 2.2 (1.8) 2.5 (2.3) 2.0 (1.9)
CDR
Mild, 0.5e1 19 (13.3) 14 (10.8) 13 (9.4) 20 (14.8) 17 (12.5) 16 (11.7)
Moderate, 2 59 (41.3) 53 (40.8) 49 (35.5) 63 (46.7) 51 (37.5) 61 (44.5)
Severe, 3 65 (45.5) 63 (48.5) 76 (55.1) 52 (38.5) 68 (50.0) 60 (43.8)
FAST
Mild 19 (13.3) 11 (8.5) 7 (5.1) 23 (17.0) 13 (9.6) 17 (12.4)
Moderate 8 (5.6) 8 (6.2) 7 (5.1) 9 (6.7) 6 (4.4) 10 (7.3)
Moderately severe 92 (64.3) 84 (64.6) 91 (65.9) 85 (63.0) 89 (65.4) 87 (63.5)
Severe 24 (16.8) 27 (20.8) 33 (23.9) 18 (13.3) 28 (20.6) 23 (16.8)
NPI-NH total score* 15.3 (16.3) 18.1 (17.4) 17.6 (17.2) 15.6 (16.4) 14.7 (16.5) 18.5 (17.0)
NPI-NH apathy scorey 2.0 (3.2) 2.7 (3.7) 2.2 (3.4) 2.4 (3.5) 2.1 (3.3) 2.6 (3.5)
CMAI total score 47.2 (15.8) 48.9 (18.0) 49.1 (16.6) 46.9 (17.1) 47.1 (15.9) 49.0 (17.8)
CSDD total score 4.4 (4.0) 5.6 (4.8) 5.3 (4.2) 4.7 (4.7) 4.7 (4.2) 5.3 (4.7)
RAID total score 4.8 (4.4) 5.6 (5.6) 5.3 (4.8) 5.1 (5.2) 5.2 (5.0) 5.2 (5.1)
CANE total number of needs 15.0 (2.6) 15.3 (2.8) 15.6 (2.9) 14.7 (2.5) 15.3 (2.5) 15.0 (2.9)
DEMQoL total score 105.9 (9.4) 102.2 (15.0) 106.0 (11.8) 102.4 (12.9) 105.0 (12.1) 103.3 (12.8)
Currently on antipsychotics 25 (17.5) 23 (17.7) 13 (9.4) 35 (25.9) 29 (21.3) 19 (13.9)
*Total score of all 12 domains of NPI-NH.
yNPI-NH G domain apathy scores.
Table 3
Clinical Correlates of Apathy* Among People With Dementia Living in Nursing
Homes
Clinical variable At baseliney
(n ¼ 273)
Pz At follow-up,x
n ¼ 191
Pz
CDR score 0.34 <0.001 0.37 <.001
FAST score 0.26 <0.001 0.29 .002
NPI-NH total scorejj 0.58 <0.001 0.46 <.001
CMAI total score 0.31 <0.001 0.16 1.00
CSDD total score 0.26 <0.001 0.13 1.00
RAID total score 0.13 1.00 0.03 1.00
CANE total score 0.33 <0.001 0.16 1.00
DEMQoL total score 0.15 0.70 0.08 1.00
*NPI-NH G domain, apathy, scores ranging from 0 to 12.
yTotal score of all 12 domains of NPI-NH.
zP values after Bonferroni correction for multiple testing.
xSpearman correlation coefficients after 9 months follow-up.
jjSpearman correlation coefficients after 9 months follow-up.
Table 4
Changes in the Severity of Apathy* Following Antipsychotic Review and Non-
pharmacological Interventions in People With Dementia Living in Nursing Homes
Intervention AR Alone,
n ¼ 43
AR and SI,
n ¼ 31
AR and EX,
n ¼ 27
Baseline apathy score,
mean (SD)
1.37 (2.02) 1.77 (3.27) 2.74 (3.89)
Antipsychotic use at
baseline, n (%)
6 (13.95) 1 (3.23) 9 (33.33)
Follow-up apathy score,
mean (SD)
4.13 (4.13) 2.28 (3.58) 1.05 (2.16)
Changes in apathy from
baseline to
follow-up, mean (SD)
2.75 (4.09) 0.36 (4.10) 1.05 (4.13)
Discontinuing
antipsychotics, n (%)y
5 (11.63) 0 (0.00) 2 (7.41)
Unadjusted difference
in apathy between the
groups, mean (SD)z
5.58 (4.31) 3.19 (4.35) 1.78 (4.39)
Adjusted difference in
apathy between the
groups, bx
5.37 5.84 7.54
95% CI of bjj 3.58e7.15 8.10 to 3.58 9.35 to 5.72
z 5.90 5.06 8.14
P <.001 <.001 <.001
*Neuropsychiatric inventory- nursing home version (NPI-NH) G domain, apathy,
scores.
yNumber of people who were on antipsychotics at baseline but not on antipsy-
chotics at the follow-up.
zUnadjusted differences among the changes in the severity of apathy from
baseline to follow-up between the intervention arm and the participants who did
not receive any interventions except PCC (n ¼ 33).
xRegression coefficients, estimated by multilevel mixed effects linear regression
model with the changes in the severity of apathy as the dependent variable, nursing
homes as the clustering variable, various interventions as the independent vari-
ables, and age and gender of the participants, as well as FAST and CSDD scores at
baseline as covariates. Participants who did not receive any interventions except
PCC formed the reference group (n ¼ 33).
jjClustered robust SEs were calculated with nursing homes as the clustering
variable.
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symptoms. Worsening of apathy over 9 months of follow-up was
significantly associated with increased overall needs, and with
worsening quality of life. Importantly, antipsychotic review was
associated with worsening apathy. However, when antipsychotic
review was undertaken in combination with social interaction or
personalized exercise, this not only mitigated the apparent detri-
mental impact but led to significant improvement. Changes in the
severity of apathy were not significantly correlated with the changes
in the severity of depressive symptoms, providing further evidence
that apathy is an independent neuropsychiatric syndrome. Correla-
tions of apathy with CMAI, CSDD, and RAID scores were not statis-
tically significant after follow-up. This finding may be explained
either by smaller numbers at the follow-up or by distinct progressive
courses of these neuropsychiatric symptoms associated with
dementia.
The detrimental impact of antipsychotic review on apathy is an
important point, and consistent with detrimental effects on other
neuropsychiatric symptoms.20 Antipsychotic review was conducted
by following guidance on managing neuropsychiatric symptoms that
was published during the UK government drive to reduce antipsy-
chotic use in the past 5 years, which has led to substantial reductions.
This guidance has led to a shift in the landscape of antipsychotic
prescribing in the United Kingdom whereby people now receiving
antipsychotic medications have more severe neuropsychiatric symp-
toms than the previous cohorts. The additional evidence from this
study that discontinuation of antipsychotics also affects apathy adds
weight to the need for review of the existing guidelines, including
greater emphasis on the use of evidence-based nonpharmacological
interventions in conjunction with antipsychotic review.
Prevalence of apathy among the participants of this study was
similar to the mean prevalence of apathy, reported by a recent sys-
tematic review,9 in people with dementia living in nursing homes. Our
findings corroborate previous studies that have reported the impor-
tance of apathy in increasing needs and worsening quality of life of
people with dementia.12,19,39 Categorical presence of apathy among
the participants did not change significantly between the 2 time
points of this study. Moreover, apathy and depressive symptoms
differed on their courses and their responses to study interventions.20
Such persistence, prognostic significance, and distinctness from
depression argue for the nosological validity of apathy as a separate
neuropsychiatric syndrome. Recognizing apathy as a separate syn-
drome and validating proposed diagnostic criteria for apathy40 will
reduce underrecognition41 and should lead to improvement of its
management in people with dementia.
Strengths of this study include a robust design, with a relatively
large sample size and long follow-up period, the inclusion of people
with moderately severe and severe dementia, and high retention of
surviving participants. The interventions followed best practice
guidelines for antipsychotic review and evidence-based approaches
for social interaction as well as exercise, and analyses explored the
effects of combined interventions. Selection bias was minimized by
randomization, and by including all eligible consenting residents in
the nursing homes. Observer bias was reduced by blinding the
research assistants, who assessed outcomes, to intervention alloca-
tion. Contamination was avoided by the cluster RCT design. It is
important to acknowledge some limitations of the study. Definition of
apathy is still evolving,42 and standardized assessment guidelines to
diagnose apathy are lacking.6,10 Reduction of apathy was not the pri-
mary outcome of the WHELD trial, and the randomization did not
stratify the participants on the presence of apathy.20 Moreover, our
analyses considered all subtypes of dementia as 1 category, but the
effects of studied interventions on apathy in people with various
subtypes of dementia may differ. Furthermore, the pragmatic nature
of this RCT allowed including people with multiple concurrent
medications.
Weak evidence base for available nonpharmacological in-
terventions for apathy in people with dementia may be attributed to
poor quality of research rather than lack of efficacy of these in-
terventions.10 Apathy in people with dementia, including those with
severe dementia living in nursing homes, can be approached with
therapeutic optimism. Significant reduction in the severity of apathy
can be achieved, if judicial review of pharmacological interventions is
combined with appropriate nonpharmacological interventions. Stan-
dardizing assessment guidelines and diagnostic criteria for apathy is
essential to evaluate the efficacy of potential interventions, and to
investigate the neurobiological mechanisms underlying apathy. More
large and rigorous RCTs investigating the efficacy of combined phar-
macological and nonpharmacological interventions to reduce apathy
in people with dementia are needed.
Conclusion
This study confirms the high prevalence and impact of apathy in
people with dementia living in nursing homes. Of particular note,
review of antipsychotic medication as a single therapeutic interven-
tion led to a significant worsening in apathy. However, undertaking
antipsychotic review in conjunction with the implementation of
evidence-based nonpharmacological interventions led to significant
improvements. The results emphasize the importance of amending
current best practice guidelines to emphasize the importance of
implementing nonpharmacological interventions as part of the pro-
cess of reviewing and discontinuing antipsychotic medication in
people with dementia.
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